Investors: Press Releases

Press Releases

February 11, 2021
NexImmune Announces Pricing of Upsized Initial Public Offering
January 19, 2021
NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member
January 18, 2021
Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer
January 4, 2021
NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
December 7, 2020
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
November 4, 2020
NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting
October 27, 2020
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia
October 6, 2020
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
September 23, 2020
NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)
June 1, 2020
NexImmune to Present at the Jefferies Virtual Healthcare Conference
Displaying 51 - 60 of 73